Recombinant human interleukin 2△1Ala125Ser

注射用重组人白介素-2△1Ala125Ser

Report date: 2024/08/07 20:00:43

Base Information

Drug NameRecombinant human interleukin 2△1Ala125Ser
Drug Alias NameSecond generation recombinant interleukin-2 (3SBio)
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionInterleukin-2 receptor agonists
TargetsInterleukin-2 receptor
Therapy Area/IndicationsCarcinoma, Renal CellMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusDiscontinued (NDA/BLA)
Highest Status in ChinaDiscontinued
Originator CompaniesShenyang Sunshine Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesShenyang Sunshine Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsCarcinoma, Renal CellMelanoma

Other Information

ATC CodeN/A
Related LinksN/A